Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700776 · ClinicalTrials.gov registry record
1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer
A clinical trial, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- 417
- Enrollment target
NCT02700776 is a clinical trial that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 417 participants.
The verdict
NCT02700776 was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- 417 participants
- Enrollment target
Study Summary
The purpose of this study is find out if a protein level in the blood (called PC Cell Derived Growth Factor or glycoprotein 88 \[GP88\]), combined with standard mammography screening, can help detect breast cancer better than mammography screening alone. Earlier research has shown that a certain glycoprotein 88 (GP88) is higher in women with breast cancer. In this study, investigators will measure the level of GP88 in the blood of healthy women who are having mammography screening for breast cancer. The investigator plans to correlate the results of the mammogram with the GP-88 level.
Interventions
- OTHER Phlebotomy - Blood sampling for GP88 at MM
- PROCEDURE SOC Tissue biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 417 participants |
| Start Date | 2014-04 |
| Est. Completion | 2017-02-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02700776
The ClinicalTrials.gov registry entry for NCT02700776 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 417 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Phlebotomy - Blood sampling for GP88 at MM is the first listed.
NCT02700776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02700776 about?
NCT02700776 is a clinical study titled "1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer". The purpose of this study is find out if a protein level in the blood (called PC Cell Derived Growth Factor or glycoprotein 88 \[GP88\]), combined with standard mammography screening, can help detect breast cancer better than mammography screening alone. Earlier research has shown that a certain gly...
What is the current status of trial NCT02700776?
This trial is currently terminated. The enrollment target is 417 participants. The study started on 2014-04. Estimated completion is 2017-02-27.
What interventions are being tested in trial NCT02700776?
The interventions under investigation include: Phlebotomy - Blood sampling for GP88 at MM (OTHER), SOC Tissue biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02700776?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.